Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Sells $42,427.28 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Jeff E. Knight sold 956 shares of the firm’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $44.38, for a total transaction of $42,427.28. Following the transaction, the chief operating officer now directly owns 52,580 shares of the company’s stock, valued at approximately $2,333,500.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Crinetics Pharmaceuticals Trading Up 3.0 %

NASDAQ:CRNX opened at $44.79 on Monday. The stock has a fifty day moving average price of $46.36 and a 200 day moving average price of $42.04. Crinetics Pharmaceuticals, Inc. has a 12-month low of $15.76 and a 12-month high of $53.70. The firm has a market cap of $3.53 billion, a PE ratio of -11.85 and a beta of 0.64.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Crinetics Pharmaceuticals had a negative return on equity of 42.50% and a negative net margin of 4,223.27%. The company had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.20 million. During the same period in the prior year, the firm posted ($0.85) earnings per share. The business’s quarterly revenue was down 76.1% compared to the same quarter last year. Equities analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.53 EPS for the current year.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

A number of large investors have recently modified their holdings of CRNX. Alps Advisors Inc. lifted its position in shares of Crinetics Pharmaceuticals by 1.6% during the 3rd quarter. Alps Advisors Inc. now owns 40,328 shares of the company’s stock worth $1,199,000 after purchasing an additional 618 shares during the last quarter. Comerica Bank purchased a new stake in Crinetics Pharmaceuticals during the 1st quarter worth about $33,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 38,087 shares of the company’s stock worth $1,783,000 after acquiring an additional 927 shares in the last quarter. Quarry LP acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth about $36,000. Finally, AJOVista LLC purchased a new position in shares of Crinetics Pharmaceuticals in the 4th quarter valued at about $58,000. 98.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. JMP Securities restated a “market outperform” rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a research report on Tuesday, June 4th. Oppenheimer lifted their price target on Crinetics Pharmaceuticals from $55.00 to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. Piper Sandler increased their price target on Crinetics Pharmaceuticals from $56.00 to $97.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Jonestrading upped their target price on Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. Finally, Robert W. Baird boosted their target price on shares of Crinetics Pharmaceuticals from $52.00 to $62.00 and gave the stock an “outperform” rating in a research note on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Crinetics Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $62.50.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.